Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

Breast Cancer Clinical Trial

Official title:

Targeting Insulin Feedback to Enhance Alpelisib (TIFA): A Phase 2 Randomized Control Trial in Metastatic PIK3CA-mutant Hormone-Receptor Positive Breast Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05090358
• Other study ID #: 21-123
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 8, 2021
• Est. completion date: October 8, 2024

Study information

• Verified date: April 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study to find out whether a very low carbohydrate diet (ketogenic diet), a low carbohydrate diet, or the study drug canagliflozin can prevent high blood sugar and may improve the effectiveness of cancer therapy in people who are receiving standard treatment with alpelisib and fulvestrant for their metastatic PIK3CA-mutant breast cancer.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 15
• Est. completion date: October 8, 2024
• Est. primary completion date: October 8, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed metastatic HR-positive, HER2-negative breast cancer. HR positive is defined by ER status >10% immunohistochemical (IHC) staining of any intensity. HER2 negativity is defined as the following as per the 2018 American Society of

Clinical Oncology and College of American Pathologists guidelines:

• IHC score of 0 or 1+ or

• Single-probe average HER2 copy number of <4 signals/cell or

• Dual-probe HER2/CEP17 ratio <2 with an average HER2 copy number of <4 signals/cell or

• IHC 0, 1+, or 2+ and dual-probe HER2/CEP17 ratio =2 with an average HER2 copy number of <4 signals/cell or

• IHC 0 or 1+ and dual-probe HER2/CEP17 ratio <2 with an average HER2 copy number of =6 signals/cell or

• IHC 0 or 1+ and dual-probe HER2/CEP17 ratio <2 with an average HER2 copy number of =4 and <6 signals/cell.

• Presence of one or more activating PIK3CA mutations in tumor tissue.

• Measurable or non-measurable disease per RECIST v1.1 OR at least one predominantly lytic bone lesion must be present.

• Written informed consent provided

• Female or male =18 years of age

• Adequate archived tumor tissue for the analysis of PIK3CA mutational status or evaluable circulating tumor DNA (ctDNA) for analysis of PIK3CA mutation status

• Recurrence or progression of disease during or after endocrine-based therapy

• Eastern Cooperative Oncology Group performance status of 0 or 1.

• Life expectancy =6 months.

• Adequate organ and marrow function as defined below:

• Hemoglobin =9.0 g/dL (without blood transfusion within 7 days of laboratory test used to determine eligibility)

• Absolute neutrophil count =1.5 × 109/L (without granulocyte colony stimulating factor support within 2 weeks of laboratory test used to determine eligibility)

• Platelet count =100 × 109/L (without transfusion within 2 weeks of laboratory test used to determine eligibility)

• Total bilirubin (TB) =1.0 × institutional upper limit of normal (ULN; Patients with known Gilbert's disease who have TB =3 × ULN may be enrolled)

• Aspartate transaminase/alanine transaminase =2.5 × ULN with normal alkaline phosphatase (=5 × ULN for patients with liver metastases) OR =1.5 × ULN in conjunction with alkaline phosphatase >2.5 × ULN

• Creatinine =1.5 mg/dL.

• Fasting blood glucose =140 mg/dL and HbA1c <8% (both criteria have to be met) and not on anti-hyperglycemic medications other than metformin (i.e., metformin is allowable if fasting blood glucose and HbA1c parameters are met).

• Able to swallow oral medication.

• Willing to be randomized to any of the diet arms and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations

• Women must be of postmenopausal status. Postmenopausal status is defined by any one of the following criteria:

• Prior bilateral oophorectomy or current ovarian suppression with a GnRH agonist

• Age =60 years

• Age <60 years and amenorrheic for at least 12 months (spontaneous cessation of menses for 12 consecutive months or more in the absence of chemotherapy

Exclusion Criteria:

• Multiple prior lines of chemotherapy in the metastatic setting (One line of chemotherapy is allowed. Also prior treatment with CDK4/6 inhibitors is allowed)

• Currently participating in a study of an investigational agent

• Current participation in a formalized weight loss program or currently consuming a ketogenic diet

• Body mass index < 20 kg/m^2

• Known hypersensitivity to alpelisib, fulvestrant, canagliflozin, or to any of the excipients of alpelisib or fulvestrant.

• Concurrent malignancy (basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or cervical cancer in situ that have undergone curative intent therapy are allowed)

• Type 1 diabetes mellitus

• Uncontrolled type 2 diabetes mellitus (hemoglobin A1c =8.0)

• Type 2 diabetes mellitus requiring treatment with a sulfonylurea, meglitinide, SGLT2 inhibitors or insulin.

• Vegetarian or vegan eating habits.

• Allergy or intolerance to egg, gluten, nut or milk protein that would interfere with adherence to diet.

• Individuals with impaired decision making capacity

Related Conditions & MeSH terms

• Breast Cancer
• Breast Cancer Stage IV
• Breast Neoplasms
• Metastatic Breast Cancer

Intervention

Dietary Supplement:
• Ketogenic Diet
Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.
• Low Carbohydrate Diet
Properly formulated meals will be provided to both diet groups for the first 12 weeks to facilitate compliance in women with metastatic breast cancer prescribed alpelisib. After 12 weeks, subjects on the two dietary arms will be given the option to cross-over to the other diet arm and continue the prescribed dietary formulation. The decision to cross over will be per patient preference.

Drug:
• Alpelisib
The recommended dose of PIQRAY is 300 mg (two 150 mg film-coated tablets) taken orally, once daily, with food. Patients should take their dose of PIQRAY at approximately the same time each day.
• Fulvestrant
The recommended dose is 500 mg to be administered intramuscularly into the buttocks slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on days 1, 15, 29 and once monthly thereafter.
• Canagliflozin
Canagliflozin is an inhibitor of SGLT2, the transporter responsible for reabsorbing the majority of glucose filtered by the kidney. For the first week of canagliflozin dosing, the dose will be 100 mg. Starting week 2 and onward the dose will be 300 mg and supplied by the site.

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge	New Jersey
United States	Ohio State University (Data Collection & Data Analysis)	Columbus	Ohio
United States	Memorial Sloan Kettering Suffolk - Commack (Limited protocol activity)	Commack	New York
United States	Memorial Sloan Kettering Westchester (All protocol Activities)	Harrison	New York
United States	Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown	New Jersey
United States	Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale	New Jersey
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Weill Cornell Medical College (Data Collection & Data Analysis)	New York	New York
United States	Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Uniondale	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hyperglycemia-free rate for participants	To determine the grade 3/4 hyperglycemia-free rate at 12 weeks, as assessed by the NCI CTCAE v5.0	12 weeks

External Links

•   Memorial Sloan Kettering Cancer Center